Publications by authors named "Robert Redd"

36Publications

Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma.

Circulation 2020 Oct 26;142(17):1687-1690. Epub 2020 Oct 26.

Adult Cancer Survivorship Program (S.G., A.N.), Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.048100DOI Listing
October 2020

Single 6-mg dose of rasburicase: The experience in a large academic medical center.

J Oncol Pharm Pract 2019 Sep 15;25(6):1349-1356. Epub 2018 Aug 15.

1 Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155218791333DOI Listing
September 2019

Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.

Hematol Oncol 2018 Oct 28;36(4):633-637. Epub 2018 Jun 28.

Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2515
Publisher Site
http://dx.doi.org/10.1002/hon.2515DOI Listing
October 2018

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

J Clin Oncol 2018 04 2;36(10):942-950. Epub 2018 Feb 2.

Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Philippe Armand, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Geraldine S. Pinkus, Azra H. Ligon, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer, VU University Medical Center; Jan Paul De Boer, Antoni van Leeuwenhoek Hospital, Lunenburg Phase I/II Consortium, Amsterdam, the Netherlands; Stephanie Sasse, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas University, Rozzano, Milan; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; John Timmerman, University of California, Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Emory University, Atlanta, GA; John Kuruvilla, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Kerry J. Savage, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, British Columbia, Canada; Marek Trneny, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic; Stephen Ansell, Mayo Clinic, Rochester, MN; and Kazunobu Kato, Benedetto Farsaci, and Anne Sumbul, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.3994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877802PMC
April 2018

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

N Engl J Med 2017 02;376(6):536-547

From the Department of Medical Oncology, Division of Hematological Malignancies (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611604DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438571PMC
February 2017

The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.

Am J Hematol 2016 10 4;91(10):E436-41. Epub 2016 Aug 4.

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24485DOI Listing
October 2016

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

J Clin Oncol 2016 08 11;34(23):2690-7. Epub 2016 Apr 11.

Margaretha G.M. Roemer, Robert A. Redd, Heather Homer, Courtney F. Connelly, Gordon J. Freeman, Philippe Armand, Bjoern Chapuy, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Azra H. Ligon, Heather H. Sun, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer and Daphne de Jong, VU University Medical Center, Amsterdam, the Netherlands; and Ranjana H. Advani, Yasodha Natkunam, Sarah E. Daadi, and Richard T. Hoppe, Stanford University Medical Center, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019753PMC
August 2016

Extramedullary Waldenström macroglobulinemia.

Am J Hematol 2015 Feb 19;90(2):100-4. Epub 2014 Nov 19.

Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23880DOI Listing
February 2015